市场调查报告书
商品编码
1561655
2024-2032 年按产品类型(试剂和消耗品、设备)、技术(色谱、免疫测定等)、最终用户(实验室、医院、研究中心)和地区分類的血红蛋白测试市场报告Hemoglobin Testing Market Report by Product Type (Reagents and Consumables, Equipment), Technology (Chromatography, Immunoassay, and Others), End-User (Laboratories, Hospitals, Research Centers), and Region 2024-2032 |
2023年,全球血红素检测市场IMARC Group达24亿美元。
血红蛋白测试可测量血液中红血球 (RBC) 的数量或血红蛋白的水平。血红蛋白是红血球中存在的一种蛋白质,它将氧气输送到器官并将二氧化碳输送回肺部。医生广泛使用血红蛋白测试作为常规检查的一部分或诊断患者的严重疾病。如果测试显示一个人体内的血红蛋白水平低于正常水平,则表示他们的红血球数量较低,并且容易出现贫血等疾病。如果红血球数高于正常值,则可能是血液疾病的征兆,也可能是由居住在高海拔地区、吸烟和脱水引起的。血红蛋白检测市场的主要最终用户是医学实验室、医院和研究中心。
贫血和糖尿病等慢性疾病的盛行率不断上升是推动全球血红素检测市场的关键因素。 2018年,全球估计有4.9亿人患有糖尿病。目前,人口老化加剧、不良饮食习惯、久坐生活方式和肥胖程度上升正在加剧糖尿病的流行。糖尿病患者需要定期接受血糖和 HbA1c 水平检测,这推动了对此类检测的需求。此外,各种健康保险政策下的血红蛋白检测优惠报销等因素也促进了市场的成长。然而,在许多国家,医疗保险并不能全额报销血红蛋白检测的费用,但透过部分支付和其他承保,消费者越来越多地采用定期和定期检测来检查和维护他们的整体健康状况。此外,卫生基础设施的改善、人均医疗保健支出的增加、对血液相关疾病的认识不断提高、人口老化、技术进步等因素预计也将在未来几年推动全球血红蛋白检测市场的发展。
The global hemoglobin testing market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032.
A hemoglobin test measures the count of red blood cells (RBC) or the level of hemoglobin in the blood. Hemoglobin is a type of protein present in the RBCs that carries oxygen to the organs and transports carbon dioxide back to the lungs. Hemoglobin tests are used extensively by doctors as a part of their routine check-ups or to diagnose a serious medical condition in the patient. If a test reveals that the hemoglobin level in an individual's body is lower than normal, it means that they have a low RBC count and are prone to disorders such as anemia. If the RBC count is higher than normal, it could be an indication for a blood disorder or can be caused by living at a high altitude, smoking and dehydration. The key end users of hemoglobin testing market are medical laboratories, hospitals and research centers.
An increasing prevalence of chronic disorders such as anemia and diabetes represent a key factor driving the global hemoglobulin testing market. In 2018, an estimated 490 Million people around the world suffered from diabetes. The prevalence of diabetes is currently being catalysed by an increasing ageing population, poor dietary habits, sedentary lifestyles and rising levels of obesity. Patients suffering from diabetes need to undergo tests to measure blood glucose and HbA1c levels regularly, driving the demand for such tests. Moreover, factors such as favourable reimbursement of hemoglobin testing under various health insurance policies is also catalyzing the growth of the market. However, in many countries, medical insurance doesn't fully reimburse the cost of hemoglobin testing, but with partial payment and other coverages, consumers are increasingly adopting regular and periodic tests in order to check and maintain their overall health. Furthermore, factors such as improving health infrastructure, increasing per capita expenditure on health care, rising awareness for blood-related ailments, ageing population, technological advancements, etc. are also projected to drive the global hemoglobin testing market in the coming years.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobin testing market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on product type, technology, and end-user.
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Bio-Rad Laboratories, Danaher, EKF Diagnostics, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Alere, ACON Laboratories, ARKRAY, Bayer Medical Care, Daiichi Biotech, DiaSys Diagnostic Systems, Epinex Diagnostics, Erba Diagnostics, etc.